The role of aldehyde oxidase in drug metabolism

被引:137
作者
Garattini, Enrico [1 ]
Terao, Mineko [1 ]
机构
[1] Ist Ric Farmacol Mario Negri, Mol Biol Lab, I-20156 Milan, Italy
关键词
aldehyde oxidase; drug discovery; drug metabolism; molybdo-enzymes; PIG LIVER SLICES; XANTHINE-DEHYDROGENASE GENE; IN-VITRO OXIDATION; GUINEA-PIG; RAT-LIVER; SUBSTRATE-SPECIFICITY; MOLYBDO-FLAVOENZYMES; DEVELOPMENTAL-CHANGES; TISSUE DISTRIBUTION; MOLECULAR-CLONING;
D O I
10.1517/17425255.2012.663352
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Aldehyde oxidases (AOXs) are molybdo-flavoenzymes with complex evolutionary profiles, as the number and types of active AOX genes vary according to the animal species considered. Humans and higher primates have a single functional AOX1 gene, while rodents are endowed with four AOXs. Along with the endoplasmic cytochrome P450 system (CYP450), cytoplasmic AOX1 is the major enzyme involved in the hepatic phase I metabolism of numerous xenobiotics. Areas covered: The authors review literature to highlight the fact that aldehydes are not the only AOX substrates, as aza- and oxo-heterocycles, that represent the scaffold of many drugs, are also oxidized efficiently by these enzymes. Additionally, the ndefine the different complements of AOX isoenzymes expressed in humans and animal models used in drug metabolism studies and discuss the implications. Furthermore, the authors report on human AOX1 allelic variants that alter the activity of this enzyme. Finally, they discuss the factors of potential importance in controlling the functional activity of AOX1. Expert opinion: There is evidence for an increasing relevance of AOX1 in the metabolism and clearance of new drugs, as measures aiming at controlling CYP450-dependent metabolism of prospective therapeutic agents are becoming routine. This calls for investigations into the biology, catalytic properties and substrate specificity of human AOX1.
引用
收藏
页码:487 / 503
页数:17
相关论文
共 101 条
[71]  
Rashidi MR, 1997, DRUG METAB DISPOS, V25, P805
[72]   RACIAL AND GENDER DIFFERENCES IN N-ACETYLTRANSFERASE, XANTHINE-OXIDASE, AND CYP1A2 ACTIVITIES [J].
RELLING, MV ;
LIN, JS ;
AYERS, GD ;
EVANS, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (06) :643-658
[73]   Inhibition of zaleplon metabolism by cimetidine in the human liver:: in vitro studies with subcellular fractions and precision-cut liver slices [J].
Renwick, AB ;
Ball, SE ;
Tredger, JM ;
Price, RJ ;
Walters, DG ;
Kao, J ;
Scatina, JA ;
Lake, BG .
XENOBIOTICA, 2002, 32 (10) :849-862
[74]   Identification of aldehyde oxidase 1 and aldehyde oxidase homologue 1 as dioxin-inducible genes [J].
Rivera, SP ;
Choi, HH ;
Chapman, B ;
Whitekus, MJ ;
Terao, M ;
Garattini, E ;
Hankinson, O .
TOXICOLOGY, 2005, 207 (03) :401-409
[75]   METHADONE - A POTENT INHIBITOR OF RAT-LIVER ALDEHYDE OXIDASE [J].
ROBERTSON, IGC ;
GAMAGE, RSKA .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (03) :584-587
[76]   CYTOSOL MEDIATED METABOLISM OF THE EXPERIMENTAL ANTITUMOR AGENT ACRIDINE CARBOXAMIDE TO THE 9-ACRIDONE DERIVATIVE [J].
ROBERTSON, IGC ;
PALMER, BD ;
OFFICER, M ;
SIEGERS, DJ ;
PAXTON, JW ;
SHAW, GJ .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (10) :1879-1884
[77]   Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver [J].
Rochat, B ;
Kosel, M ;
Boss, G ;
Testa, B ;
Gillet, M ;
Baumann, P .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (01) :15-23
[78]  
RODRIGUES AD, 1994, BIOCHEM PHARMACOL, V48, P197
[79]  
RODRIGUES AD, 1994, DRUG METAB DISPOS, V22, P788
[80]   Convergent neofunctionalization by positive Darwinian selection after ancient recurrent duplications of the xanthine dehydrogenase gene [J].
Rodríguez-Trelles, F ;
Tarrío, R ;
Ayala, FJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) :13413-13417